MoonLake Immunotherapeutics Class A MLTX 深 沪
已收盘 07-02 16:00:00 美东时间
18.95
-0.180
-0.94%
华盛通- 最 高19.31
- 今 开19.20
- 成交量 139.19万股
- 最 低 18.57
- 昨 收 19.13
- 总市值 13.63亿
- 52周最高 62.75
- 市盈率 静 --
- 换手率 1.94%
- 52周最低 5.95
- 委 比 -30.34%
- 总股本 7189.98万
- 历史最高 64.98
- 量 比 0.98
- 振 幅 3.87%
- 历史最低 4.25
- 每 手 1
- 风险率 16.78%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅392.61%！Chardan Capital维持EyePoint"买入"评级，上调目标价至65美元
今日重点评级关注：Chardan Capital：维持EyePoint"买入"评级，目标价从29美元升至65美元；康托·菲茨杰拉德：维持Hyperliquid Strategies"超配"评级，目标价从8美元升至18.4美元
07-02 18:41
Leerink Partners Maintains Outperform on MoonLake, Raises Price Target to $29
Leerink Partners analyst Thomas Smith maintains MoonLake (NASDAQ:MLTX) with a Outperform and raises the price target from $24 to $29.
07-01 21:23
Why Is MoonLake Immunotherapeutics Stock Soaring Monday?
MoonLake Immunotherapeutics (NASDAQ:MLTX) stock is trading higher on Monday after the company reported encouraging 52-week results from its Phase 3 VELA-1 and VELA-2 studies evaluating sonelokimab (SLK) for moderate-to-severe hidradenitis suppurativa (HS). The data released on Sunday showed sustaine...
06-22 20:03
Why Sagtec Global Shares Are Trading Higher By Around 76%; Here Are 20 Stocks Moving Premarket
Shares of SAGTEC GLOBAL Ltd (NASDAQ:SAGT) gained 75.6% to $1.74 in pre-market trading after the Kuala Lumpur-based enterprise software firm issued financial year 2026 guidance projecting 35% revenue growth. Sagtec projected $25.78 million in revenue, up from $19.1 million in the financial year 2025....
06-22 17:21
美股夜盘 | MoonLake Immunotherapeutics Class A涨10.57%，最新股价21.24美元
MoonLake Immunotherapeutics Class A涨10.57%，报21.24美元
06-22 08:20
美股大行评级 | 潜在涨幅321.55%！Shattuck Labs获花旗升目标价至18美元，维持"买入"评级
今日重点评级关注：花旗：维持Shattuck Labs"买入"评级，目标价从7美元升至18美元；Benchmark：维持Gloo Holdings"买入"评级，目标价从14美元升至15美元
06-10 12:32
BTIG Reiterates Buy on MoonLake, Maintains $30 Price Target
BTIG analyst Julian Harrison reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $30 price target.
06-09 18:37
美股大行评级 | 存储再获看多！美光、闪迪、西部数据获机构上调目标价；次新股Cerebras、Blackstone、EagleRock获多家机构首予买入平均
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.25美元升至5.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从9美元升至9.25美元
06-09 11:33
Moonlake Immunotherapeutics Inks Master Commercial Supply Agreement With Vetter Pharma To Manufacture One Or More Application Systems Pre-filled With An Active Pharmaceutical Ingredient, Placebo Or Other Material For Moonlake-8K
On May 22, 2026, MoonLake Immunotherapeutics (the "Company") entered into a Master Commercial Supply Agreement (the "Vetter MCSA") with Vetter Pharma International GmbH ("Vetter"). Pursuant to the Vetter MCSA,
06-01 19:18
美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
